🚀 VC round data is live in beta, check it out!
- Public Comps
- Aelis Farma
Aelis Farma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aelis Farma and similar public comparables like Diamyd Medical, Alligator Bioscience, AcuCort, Biotechnology Assets and more.
Aelis Farma Overview
About Aelis Farma
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.
Founded
2013
HQ

Employees
23
Website
Sectors
Financials (LTM)
EV
$16M
Aelis Farma Financials
Aelis Farma reported last 12-month revenue of $2M.
In the same LTM period, Aelis Farma generated had net loss of ($7M).
Revenue (LTM)
Aelis Farma P&L
In the most recent fiscal year, Aelis Farma reported revenue of $3M and EBITDA of ($8M).
Aelis Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $3M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (250%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (289%) | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (309%) | XXX | (278%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aelis Farma Stock Performance
Aelis Farma has current market cap of $21M, and enterprise value of $16M.
Market Cap Evolution
Aelis Farma's stock price is $1.53.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $21M | -1.7% | XXX | XXX | XXX | $-0.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAelis Farma Valuation Multiples
Aelis Farma trades at 6.8x EV/Revenue multiple, and (2.1x) EV/EBITDA.
EV / Revenue (LTM)
Aelis Farma Financial Valuation Multiples
As of April 19, 2026, Aelis Farma has market cap of $21M and EV of $16M.
Equity research analysts estimate Aelis Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aelis Farma has a P/E ratio of (2.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.8x) | XXX | XXX | XXX |
| P/E | (2.8x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aelis Farma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Aelis Farma Margins & Growth Rates
Aelis Farma's revenue in the last fiscal year declined by (24%).
Aelis Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
Aelis Farma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (24%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (250%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 49% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 371% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 389% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aelis Farma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aelis Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Diamyd Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| AcuCort | XXX | XXX | XXX | XXX | XXX | XXX |
| Biotechnology Assets | XXX | XXX | XXX | XXX | XXX | XXX |
| Active Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aelis Farma M&A Activity
Aelis Farma acquired XXX companies to date.
Last acquisition by Aelis Farma was on XXXXXXXX, XXXXX. Aelis Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aelis Farma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAelis Farma Investment Activity
Aelis Farma invested in XXX companies to date.
Aelis Farma made its latest investment on XXXXXXXX, XXXXX. Aelis Farma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aelis Farma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aelis Farma
| When was Aelis Farma founded? | Aelis Farma was founded in 2013. |
| Where is Aelis Farma headquartered? | Aelis Farma is headquartered in France. |
| How many employees does Aelis Farma have? | As of today, Aelis Farma has over 23 employees. |
| Is Aelis Farma publicly listed? | Yes, Aelis Farma is a public company listed on Euronext Paris. |
| What is the stock symbol of Aelis Farma? | Aelis Farma trades under AELIS ticker. |
| When did Aelis Farma go public? | Aelis Farma went public in 2022. |
| Who are competitors of Aelis Farma? | Aelis Farma main competitors are Diamyd Medical, Alligator Bioscience, AcuCort, Biotechnology Assets. |
| What is the current market cap of Aelis Farma? | Aelis Farma's current market cap is $21M. |
| What is the current revenue of Aelis Farma? | Aelis Farma's last 12 months revenue is $2M. |
| What is the current revenue growth of Aelis Farma? | Aelis Farma revenue growth (vs. last FY) is (24%). |
| What is the current EV/Revenue multiple of Aelis Farma? | Current revenue multiple of Aelis Farma is 6.8x. |
| Is Aelis Farma profitable? | No, Aelis Farma is not profitable. |
| What is the current net income of Aelis Farma? | Aelis Farma's last 12 months net income is ($7M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.